2Seventy Bio, Inc. (NASDAQ:TSVT) Q4 2023 Earnings Conference Call March 5, 2024 8:00 AM ET

Company Participants

Elizabeth Hickin - Head, IR

Chip Baird - Incoming CEO

Vicki Eatwell - Incoming CFO

Anna Truppel-Hartmann - SVP, Clinical Development

Conference Call Participants

Daina Graybosch - Leerink Partners

Tommie Reerink - Goldman Sachs & Co.

Kelsey Goodwin - Guggenheim Securities

Samantha Semenkow - Citigroup

Operator

Good day, and thank you for standing by. Welcome to the 2seventy bio fourth-quarter 2023 earnings conference call. [Operator Instructions].

Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Elizabeth Hickin, Head of Investor Relations. Please go ahead.

Elizabeth Hickin

Thank you, operator, and good morning, everyone. Thank you for joining us.

This morning, we issued a press release on our fourth-quarter and full-year 2023 financial results. The press release can be found in the Investors and Media section of the company's website at 2seventy bio.com.

As a reminder, today's discussion will include forward-looking statements related to 2seventy bio's current plans and expectations, which are subject to certain risks and uncertainties. These forward-looking statements include statements regarding our strategic plans, timelines, and expectations with respect to sales, efficacy, and perceived therapeutic benefits of ABECMA, the timing and review of additional studies and regulatory applications for ABECMA, and statements regarding our financial condition. expectations. and future financial results among others.

Actual results may differ materially due to various risks, uncertainties, and other factors including those described in the risk factors section of our most recent Form 10-K, quarterly reports, and other SEC filings. These forward-looking statements represent our views as of this call and should not be relied upon as representing our views as of any subsequent date. You are cautioned not to place any undue reliance on these forward-looking statements and except as required by law, we undertake no obligation to update or revise any forward-looking statements.

On today's call, we are joined by Chip Baird, Incoming Chief Executive Officer; and Vicki Eatwell, Incoming Chief Financial Officer. Anna Truppel-Hartmann, Head of Clinical Development, is also on the line for Q&A.

And now I will turn it over to Chip. Chip?

Chip Baird

Thank you, Liz, and thank you all for joining us.

This morning, we disclosed our fourth-quarter and full-year 2023 financial results and recent business and operational updates. I'd like to walk through some of the business updates and then Vicki Eatwell, our Incoming Chief Financial Officer, will go into detail on the financials.